Jan 13, 2010
US Expert Panel recommends the use of Fractional Exhaled Nitric Oxide (FENO) in the diagnosis and management of Asthma.
SOLNA, Sweden – 13 January 2010 – Aerocrine AB (OMX Nordic Exchange: AERO) today announced that a group of prominent clinicians and researchers, all leaders in the field of asthma in the US, has issued a consensus paper recommending that inflammation monitoring using exhaled nitric oxide should be part of the routine clinical management of asthma in conjunction with other conventional methods.
The points of clinical consensus were arrived at during a closed meeting held at National Jewish Health in Denver, Colorado.
Nov 4, 2009
Aerocrine and Panasonic Shikoku Electronics enter into asthma partnership
SOLNA, Sweden – 4 November 2009 – Aerocrine AB (OMX Nordic Exchange: AERO) today announced that Aerocrine and Panasonic Shikoku Electronics, CO., LTD (PSEC) have entered into a long-term agreement to develop, manufacture and market new generation products for airway inflammation monitoring using exhaled nitric oxide.
Sep 24, 2009
Aerocrine wins patent infringement suit against Medisoft in Germany
SOLNA, Sweden – 24 September 2009 – Aerocrine AB today announced the positive outcome of its complaint against Medisoft P.A.E. filed at the District Court of Dusseldorf, Germany.
Sep 3, 2009
Canada Approves NIOX MINO for Asthma Monitoring
SOLNA, Sweden – 3 September 2009 – Aerocrine AB today announced that Health Canada’s Therapeutic Products Directorate has approved Aerocrine’s NIOX MINO® technology for use in treating asthma. Canada’s National Health Service may now begin using the NIOX MINO, a medical device that provides a measure of the degree of inflammation in the airways in a single breath.
Aug 21, 2009
Major insurance company covers Aerocrine’s method for asthma control: Calls eNO measurement “Medically Necessary”
SOLNA, Sweden – 21 August 2009 – CareFirst BlueCross BlueShield, the largest health care insurer in the Mid-Atlantic region of the USA, has adopted a policy stating that measurement of exhaled nitric oxide (eNO) is considered medically necessary in the management of asthma patients.
Aug 19, 2009
Aerocrine provides update on its legal action against Apieron
SOLNA, Sweden – 19 August 2009 – Aerocrine AB today announced that the United States District Court has accepted Aerocrine’s motion for leave to add a third patent to its October 2008 patent infringement complaint against Apieron, Inc. Menlow Park, USA.
Mar 9, 2009
Swiss physicians to be reimbursed per NIOX MINO® test
SOLNA, Sweden—9 March 2009—Aerocrine AB (OMX Nordic Exchange: AERO) announced today that reimbursement for the routine measurement of airway inflammation has been introduced in the Swiss healthcare system.
Feb 12, 2009
Treating asthma with NIOX MINO® offers cost savings for the UK healthcare system
SOLNA, Sweden, 12 February 2009 - Aerocrine AB (OMX Nordic Exchange: AERO) has reported the recent publication of a UK study evaluating the effect of routine inflammation measurement in asthma.
Nov 12, 2008
Publication of prospectus with respect to Aerocrine´s new share issue 2008
Jun 27, 2008
China opens up to Aerocrine’s asthma test
SOLNA, Sweden, 27 June 2008—Aerocrine AB announced today that its handheld airway inflammation monitor, NIOX MINO®, has been registered for marketing and sale in China.
Aerocrine’s method of measuring airway inflammation, using exhaled nitric oxide (NO) tests, has also been incorporated into China’s national guidelines for asthma management. Tests for airway inflammation have received a reimbursement code.
Apr 8, 2008
Airway inflammation measurement receives reimbursement in Czech Republic
SOLNA, Sweden – 8 April, 2008 – Aerocrine AB (OMX Nordic Exchange: AERO) today announced that a new reimbursement code has been issued for the exhaled NO tests in the Czech healthcare system.
Mar 4, 2008
FDA Grants Market Clearance to Aerocrine Inc.’s NIOX MINO®: a New Hand-Held Device to Measure Airway Inflammation in Asthma
NIOX MINO® Set to Dramatically Improve Airway Inflammatory Disease Management through Personalized Inflammation Control.
NEW PROVIDENCE, N.J., March 4, 2008 – Aerocrine, Inc. today announced that NIOX MINO, a hand-held point-of-care device for the measurement of airway inflammation, has been 510(k) cleared by the U.S. Food and Drug Administration (FDA). Physicians in the U.S. now have a highly accurate, non-invasive and convenient technology that is appropriate for use in a doctor’s office, ultimately helping them improve how they treat asthma patients.
Feb 11, 2008
Aerocrine enters distribution agreement with Chest in Japan
SOLNA – February 11, 2008 – Aerocrine AB (OMX Nordic Exchange: AERO) announces that the company has entered into a distribution agreement with Chest M.I. Inc. Chest will market and sell NIOX MINO® in Japan.
Feb 7, 2008
Aerocrine appoints new President of Aerocrine Inc.
SOLNA, Sweden – 7 February, 2008 – Aerocrine AB (OMX Nordic Exchange: AERO) today announced the appointment of Chip Neff to the position of President of Aerocrine’s US subsidiary Aerocrine Inc., effective from 25 February 2008. Chip Neff will succeed Trevor Bourke, who has led the development of Aerocrine Inc since 2002. Trevor Bourke will remain at Aerocrine Inc during the transition, prior to taking up a new role in Europe.
Jan 14, 2008
Cost savings in asthma management when using NIOX MINO® First health economic study published
SOLNA – 14 January, 2008 – Aerocrine AB (OMX Nordic Exchange: AERO) reports that the first heath economic study evaluating the effect of introducing measurements of exhaled NO in asthma management has been published.
Jan 9, 2008
Aerocrine strengthens its patent portfolio
SOLNA – 9 January 2008 – Aerocrine AB (OMX Nordic Exchange: AERO) announces that the company has strengthened its patent portfolio by both acquiring a strategically important patent and patenting its own discoveries.
Dec 20, 2007
Aerocrine enters distribution agreement with Phadia in France
SOLNA – 20 December, 2007 – Aerocrine AB (OMX Nordic Exchange: AERO) announces that the company has entered into a distribution agreement with Phadia France.
Dec 7, 2007
NIOX® approved in China. Aerocrine expands its distribution agreement to include NIOX MINO®.
SOLNA – 7 December 2007 – Aerocrine AB (OMX Nordic Exchange: AERO) announces that the company’s NIOX product has been approved by SFDA, the Chinese registration authority. Aerocrine has also entered into a distribution agreement with Bioson Inc. that includes sales of both NIOX and NIOX MINO in China.
Oct 15, 2007
Aerocrine enters collaboration for improved treatment of asthma and intestinal diseases
SOLNA – 15 October, 2007 – Aerocrine AB (OMX Nordic Exchange: AERO) announces that it has become a partner in a program for the development of diagnostic methods for allergies, asthma and food hypersensitivity.
Oct 2, 2007
Aerocrine submits 510(k) filing for NIOX MINO® in the U.S.
SOLNA – October 2, 2007 – Aerocrine AB (OMX Nordic Exchange: AERO) announced that it has submitted a 510(k) application for marketing clearance to the U.S. Food & Drug Administration (FDA) for its NIOX MINO® device.
Sep 17, 2007
Aerocrine appoints Vice President Global Sales
SOLNA – 17 September, 2007 – Aerocrine appoints new senior sales position whereby Anna Malm Bernsten joins Aerocrine's management team from mid September with the responsibility for global sales.
Aug 24, 2007
AEROCRINE REINFORCES MANAGEMENT TEAM
SOLNA, Stockholm – 24th of August 2007 – In August Kjell Alving, Professor at the Karolinska Institute, joined Aerocrine’s management team responsible for scientific and medical affairs.
Jan 25, 2007
AEROCRINE APPOINTS NEW CEO
SOLNA, Sweden -- Jan. 25, 2007 -- Aerocrine today announced the appointment of Paul de Potocki to the position of President and Chief Executive Officer, Aerocrine AB, effective from February 1, 2007. Paul succeeds Thomas Almesjö who has led the development of Aerocrine since its foundation, and who is now moving on to assignments outside the company.
Sep 30, 2006
Swedish asthma-instrument launched into space: How much dust does an astronaut eat?
A novel instrument developed to help asthma patients is about to be launched to the International Space Station (ISS) in the frame of the European exploitation programme run by the European Space Agency (ESA). The instrument will be used to support scientific investigations on the effect of inhalation of dust particles and lung performances after space walks outside the station.
May 1, 2003
A first-of-a-kind, non-invasive test to monitor asthma - NIOX cleared by the FDA